Clinical Trial Detail

NCT ID NCT02382549
Title A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib (Mel61)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Craig L Slingluff, Jr
Indications

melanoma

Therapies

6MHP vaccine + Dabrafenib + Trametinib

Age Groups: adult senior

No variant requirements are available.